Teacher Retirement System of Texas Lowers Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Teacher Retirement System of Texas decreased its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 29.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 102,742 shares of the company's stock after selling 42,646 shares during the quarter. Teacher Retirement System of Texas' holdings in Elanco Animal Health were worth $1,244,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of ELAN. Steward Partners Investment Advisory LLC increased its position in shares of Elanco Animal Health by 28.3% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company's stock valued at $124,000 after purchasing an additional 2,264 shares during the last quarter. DDD Partners LLC purchased a new position in shares of Elanco Animal Health in the fourth quarter worth $5,974,000. Geode Capital Management LLC increased its position in shares of Elanco Animal Health by 0.8% in the third quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company's stock valued at $115,623,000 after acquiring an additional 65,303 shares during the period. Atom Investors LP raised its stake in shares of Elanco Animal Health by 310.3% during the third quarter. Atom Investors LP now owns 345,855 shares of the company's stock valued at $5,081,000 after acquiring an additional 261,559 shares during the last quarter. Finally, Harbor Capital Advisors Inc. grew its position in shares of Elanco Animal Health by 24.0% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company's stock worth $13,135,000 after buying an additional 209,734 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors.

Remove Ads

Elanco Animal Health Stock Down 1.4 %

Shares of ELAN traded down $0.14 during trading hours on Tuesday, hitting $10.36. The company had a trading volume of 1,563,674 shares, compared to its average volume of 4,773,976. Elanco Animal Health Incorporated has a 52-week low of $10.03 and a 52-week high of $18.80. The firm has a fifty day moving average price of $11.20 and a 200-day moving average price of $12.39. The stock has a market capitalization of $5.12 billion, a price-to-earnings ratio of 25.91, a P/E/G ratio of 2.50 and a beta of 1.44. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the company posted $0.08 EPS. The company's quarterly revenue was down 1.4% on a year-over-year basis. On average, equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius bought 10,000 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was bought at an average cost of $10.90 per share, for a total transaction of $109,000.00. Following the completion of the transaction, the director now owns 101,459 shares of the company's stock, valued at $1,105,903.10. This represents a 10.93 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.57% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ELAN. Leerink Partners initiated coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a "market perform" rating and a $14.00 price target on the stock. Morgan Stanley decreased their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 26th. Barclays dropped their price target on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Leerink Partnrs raised Elanco Animal Health to a "hold" rating in a research report on Monday, December 2nd. Finally, Piper Sandler reduced their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, March 6th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $15.17.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.